Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(b) Resignation of a Director.
On June13, 2017, Nina Kjellson notified the Board of Directors
(the Board) of Eiger BioPharmaceuticals, Inc. (the Company) of
her resignation as a director effective immediately. Ms.Kjellsons
resignation was not the result of any disagreement or dispute
with the Company on any matter relating to the Companys
operations, policies or practices.
(d) Appointment of a New Director.
On June14, 2017, upon recommendation of the Nominating and
Corporate Governance Committee of the Board, the Board appointed
David Apelian as a director effective immediately to fill the
vacancy created by Ms.Kjellsons resignation. The Board appointed
Dr.Apelian to serve as a member of the Board as a Class I
director for a term expiring at the Companys 2019 Annual Meeting
of Stockholders, or until his earlier death, resignation or
removal or his successor is duly elected and qualified.
There is no arrangement or understanding between Dr.Apelian and
any other person to which Dr.Apelian was appointed as a director.
Dr.Apelian is party to an indemnification agreement with the
Company and will be eligible to participate in all non-employee
director compensation plans and arrangements available to
non-employee directors. Accordingly, Dr.Apelian will be granted
an option to purchase 25,000 shares of common stock of the
Company under its 2013 Equity Incentive Plan. In addition,
Dr.Apelian will be eligible to receive an annual grant of an
option to purchase 10,000 shares of common stock of the Company
under its 2013 Equity Incentive Plan. Dr.Apelian will also be
eligible to receive cash compensation of $40,000 per year as a
director.
| Item5.07 |
Submission of Matters to a Vote of Security Holders. |
Set forth below are the proposals voted upon at the Annual
Meeting (the Annual Meeting) of Stockholders of the Company held
on June13, 2017 at 366 Cambridge Avenue, Palo Alto, California
94306, along with the final voting results thereon:
Proposal 1To elect the two Class II directors
named below to serve until the 2020 Annual Meeting of
Stockholders or until their respective successors have been duly
elected and qualified. Each of the two named nominees was so
elected, with the votes thereon at the Annual Meeting as follows:
| Final Voting Results | ||||||||||||
|
Nominees |
For | Withheld | BrokerNon- Votes | |||||||||
|
Edgar G. Engleman, M.D. |
5,866,990 | 56,577 | 909,175 | |||||||||
|
Jeffrey S. Glenn, M.D., Ph. D. |
5,886,122 | 37,445 | 909,175 |
Proposal 2To ratify the selection by the Audit
Committee of the Board of Directors of KPMG LLP as the Companys
independent registered public accounting firm for the fiscal year
ending December31, 2017. This proposal was approved by the
requisite vote, with the votes thereon at the Annual Meeting as
follows:
|
FinalVotingResults |
||||||
|
For |
Against |
Abstain |
BrokerNon-Votes |
|||
|
6,808,111 |
21,748 | 2,883 |
About Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.